

1 Review: Highlights from the 2019 International Myopia Summit on ‘Controversies in Myopia’

2

3 Chee Wai Wong^{1,2,3}, Li Lian Foo^{1,2,3}, Priya Morjaria⁴, Ian Morgan⁵, Andreas Mueller^{6,7}, Amanda
4 Davis⁸, Drew Keys⁸, Ming Guang He⁷, Padmaja Sankaridurg^{9,10}, Jian Feng Zhu¹¹, Peter Hendicott¹²,
5 Donald Tan^{2,3}, Seang Mei Saw^{2,3}, Ching Yu Cheng^{1,2,3}, Ecosse Lamoureux^{2,3}, Johnathan Crowston^{1,2,3},
6 Chui Ming Gemmy Cheung^{1,2,3}, Chelvin Sng^{2,13}, Cordelia Chan¹, Doric Wong^{1,2,3}, Shu Yen Lee^{1,2,3},
7 Rupesh Agrawal^{2,14}, Quan V. Hoang^{1,2,3,15}, Xinyi Su^{13,16,17}, Adrian Koh¹, Cheryl Ngo¹³, Hao Chen¹⁸,
8 Pei Chang Wu^{19,20}, Audrey Chia^{1,2,3}, Jost B. Jonas²¹, Tien Yin Wong^{1,2,3}, Marcus Ang^{1,2,3}

9

- 10 1. Singapore National Eye Centre, Singapore
- 11 2. Singapore Eye Research Institute, Singapore
- 12 3. Duke–NUS Medical School, National University of Singapore
- 13 4. International Centre for Eye Health, London School of Hygiene and Tropical Medicine
- 14 5. Research School of Biology, Australian National University, Australia
- 15 6. World Health Organization Regional Office for the Western Pacific
- 16 7. Centre for Eye Research Australia, Australia
- 17 8. International Agency for Prevention of Blindness, London, United Kingdom
- 18 9. Brien Holden Vision Institute, Sydney, Australia
- 19 10. School of Optometry and Vision Science, University of New South Wales, Sydney, Australia
- 20 11. Department of Preventative Ophthalmology Shanghai Eye Diseases Prevention & Treatment
21 Centre, Shanghai Eye Hospital, China
- 22 12. School of Optometry and Vision Science, Queensland University of Technology, Australia
- 23 13. Department of Ophthalmology, National University Hospital, Singapore
- 24 14. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore
- 25 15. Department of Ophthalmology, Columbia University, New York, USA
- 26 16. Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and
27 Research (A*STAR), Singapore

1 17. Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of
2 Singapore, Singapore

3 18. Department of Ophthalmology, Wenzhou Medical College, China

4 19. Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital, Taiwan

5 20. Chang Gung University College of Medicine, Taiwan

6 21. Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Germany

7
8
9
10 Corresponding author:

11 Associate Professor Marcus Ang

12 Singapore National Eye Centre

13 11 Third Hospital Avenue

14 Singapore 168751

15 Telephone number: (65) 62277255

16 Fax number: (65) 6323 1903

17 E-mail: marcus.ang@s nec.com.sg

18 Word count: 3000

19
20 Competing interests: Jost B. Jonas: Advisory Board Novartis; Patent holder with Biocompatibles UK
21 Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and
22 secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and
23 Europäische Patentanmeldung 16 720 043.5 and Patent application US 2019 0085065 A1,,Agents for
24 use in the therapeutic or prophylactic treatment of myopia or hyperopia).

1 **Abstract**

2 Myopia is an emerging public health issue with potentially significant economic and social impact in
3 populations especially from East Asia. However, many uncertainties around myopia and its clinical
4 management. The International Myopia Summit workgroup was convened by the Singapore Eye
5 Research Institute, the World Health Organization (WHO) Regional Office for the Western Pacific
6 and the International Agency for the Prevention of Blindness (IAPB) in 2019. The aim of this
7 workgroup was to summarise available evidence, identify gaps or unmet needs, and provide
8 consensus on future directions for clinical research in myopia. In this review, amongst the many
9 ‘controversies in myopia’ discussed, we highlight three main aspects: First, development of clinical
10 interventions for the prevention of ocular elongation and pathologic myopia are needed, and may
11 require multifaceted research targeting multiple sites, including the Bruch’s membrane, choroid and
12 sclera. Second, clinical myopia management requires cooperation between optometrists and
13 ophthalmologists to provide patients with holistic care, and a tailored approach that balances risks and
14 benefits of treatment by utilising both optical and pharmacological interventions. Third, the diagnosis
15 and management of myopia complications may be improved through collaboration between
16 clinicians, researchers and industry. There is an unmet need to develop new imaging modalities for
17 both structural and functional analyses and to establish normative databases for myopia in the long
18 term. In conclusion, the workgroup’s call to action advocated for a paradigm shift towards a
19 collaborative approach in the holistic clinical management of myopia.

20

21

22

23

24

25

26

27

1 **Introduction**

2 Myopia is increasingly recognised as an emerging public health issue with significant economic
3 burden particularly in East Asia.[1-5] The awareness of myopia and its impact has led to the
4 implementation of public health interventions, the study of myopia control therapies and research into
5 the treatment of myopia-related complications.[6] However, there are several unresolved questions
6 with regards to the clinical management of myopia and pathologic myopia. Thus, the International
7 Myopia Summit (IMS) workgroup was convened in 2019, supported by the World Health
8 Organisation (WHO) and the International Agency of Prevention of Blindness (IAPB).

9

10 The main aim of this workgroup was to discuss ‘controversies’ surrounding myopia, identify unmet
11 needs in myopia research and its clinical management, and provide suggestions for future
12 development in the field of myopia – **Supplementary Table 1**. The composition of the workgroup
13 consisted of representatives from 20 international organizations renowned for myopia prevention,
14 research and/or clinical management. Members of the workgroup comprised public health officials,
15 optometrists, ophthalmologists and researchers – **Supplementary Table 2**. The definitions of myopia
16 used followed recent consensus,[6-9] to ensure consistency for this workgroup meeting – **Table 1**.

17

18 In this review, we included published literature from a non-systematic review of available evidence
19 from the last 20 years up to July 2019 in MEDLINE, EMBASE and Cochrane Library, using the
20 search terms “myopia”, “high myopia”, “pathologic myopia” alone or in combination with
21 “prevalence”, “epidemiology”, “diagnosis”, “treatment”, “imaging”, “control”, “prevention”,
22 “optical”, “spectacles”, “atropine”, “contact lens” and “orthokeratology”. The reference lists from
23 articles identified by this search strategy were also used to include other relevant publications. While
24 publications on randomized clinical trials were prioritized, we also included highly regarded or
25 highly-cited publications, such as review articles and meta-analyses. Here, we present discussions on
26 three ‘controversies’ in the clinical management of myopia, highlighted by the workgroup as aspects
27 that may require further collective focus – **Figure 1**.

1

2 Table 1: Definitions of Myopia used in this review as previously defined [6-9]

Term	Definition
Myopia	Spherical equivalent refractive error ≤ -0.50 diopter
High myopia (without pathology)	Spherical equivalent refractive error ≤ -5.0 diopter
Myopic macular degeneration	A vision-threatening condition occurring in people with myopia, usually high myopia that comprises diffuse or patchy macular atrophy with or without lacquer cracks, macular Bruch's membrane defects, myopic choroidal neovascularisation and Fuchs spot.
Pathologic myopia	Excessive axial elongation associated with myopia that leads to structural changes in the posterior segment of the eye (including posterior staphyloma, myopic macular degeneration, myopic traction maculopathy, and high myopia-associated optic neuropathy) and that can lead to loss of best-corrected visual acuity.

3

4 **Controversy 1: Should research in myopia treatments focus on preventing the development of**
5 **pathologic myopia rather than prevention of myopia progression?**

6

7 There is increasing awareness that myopia is not just a refractive error that can be “reversed” by
8 optical aids or refractive surgery. Myopia may progress to pathologic myopia, a potentially blinding
9 condition due to complications such as retinal detachment, myopic maculopathies and glaucoma.[10]

10 However, current clinical management of myopia is focused on its control and reducing myopia as a
11 refractive error, rather than interventions to prevent the development of pathologic myopia and its
12 complications.[10 11] Given this context, two important aspects were highlighted and discussed:

13

14 ‘Does controlling myopia in childhood, prevent the development of pathologic myopia in adulthood?’

1 Pathologic myopia (PM) is a sight threatening condition that includes myopia macular degeneration
2 (MMD), myopic traction maculopathy, myopic choroidal neovascularization (mCNV) and myopia-
3 associated optic neuropathy.[8 10] Posterior staphyloma (PS), an outward protrusion of all layers of
4 the posterior eye globe, is a hallmark lesion of PM.[11] The prevalence of PM is closely correlated
5 with the severity of myopia.[12] The Guangzhou twin eye study demonstrated that earlier age at
6 myopia onset was associated with higher myopic refractive error at 18 years old .[13] Current myopia
7 control options can reduce progression by 50% and specifically, among children with age of onset at 8
8 years old, myopia control would reduce their mean refractive error from -6D to -3D. This level of
9 myopia control would significantly reduce the risk of PM from 30% to 5%.[14]

10

11 Conversely, PM is a complex condition with multiple non-modifiable risk factors other than axial
12 length (AL), such as age, gender and genetics.[10] With pharmaceutical treatments, AL reduction is
13 limited. Specifically in the ATOM and LAMP studies, AL increased by +0.41mm and +0.36mm in
14 the 0.01% atropine groups, respectively, compared to +0.38mm and +0.4mm with placebo.[15-18]
15 The second year follow up of LAMP Study did however report significant reduction in axial
16 elongation when children on placebo, were switched to 0.05% Atropine in the second year (0.15 vs
17 0.43 mm, $P < 0.001$ in year 2 and year 1, respectively).[19] Furthermore, eyes with shallow PS may
18 have a higher frequency of mCNV[20], suggesting that the risk of mCNV may not be closely
19 correlated with AL. Age is another important risk factor. PM and PS do not occur in children with
20 high myopia without pathology.[21 22] Men in general have longer AL than women[23], but a higher
21 prevalence of MMD and mCNV is observed in females in multivariable analyses.[24 25] Lastly,
22 genome wide association studies have identified single nucleotide polymorphisms (SNPs) for
23 refractive error[26], while the SNPs specific for PM are still unknown.[27] However, it remains
24 unclear if slowing myopia progression in individuals with high genetic risk will be effective in
25 preventing PM.

26

1 'A potential treatment target: Is the Sclera and choroid, or Bruch's membrane a primary site of
2 pathogenesis in pathologic myopia?'

3 Ophthalmoscopic features of axial myopia suggest a significant contribution of the Bruch's membrane
4 (BM) to several pathologic features including lacquer cracks (cracks in the BM), patchy/macular
5 atrophy (both are BM defects), mCNV (which arise from a break of the BM) and parapapillary
6 gamma zone (a result of the temporal shift and widening of the optic nerve head-related BM
7 opening). Histologically, BM defects in congenital colobomata and toxoplasmotic scars are
8 associated with scleral staphyloma.[28] Both choroidal and scleral volume are not associated with
9 AL, but BM increases in volume with AL.[29] This suggests that BM may have an active role in the
10 process of axial elongation. A hypothesis for the role of BM in the process of myopization states that
11 axial elongation occurs by the production of and elongation of the BM in the equatorial region.[30]
12 This explains the decrease in retinal pigment epithelium density and retinal thinning at the equator.[31
13 32] Also, the compression of the choroid against the sclera by the expanding BM results in choroidal
14 thinning.[30] Enlargement of the BM opening and development of macular BM defects may be
15 explained by the tension in BM in the coronal direction.[30] Thus, BM may be more than just an
16 almost invisible double basal membrane with some collagen and elastin in between. Further evidence
17 to support this hypothesis was demonstrated in a guinea pig model of myopia, in which intraocular
18 injection of antibodies to amphiregulin, a member of the epithelial growth factor family that regulates
19 the production of BM, was shown to decrease axial elongation in a dose dependent manner.[33 34]
20
21 There is equally strong evidence for the sclera and choroid as the primary sites of pathology in PM.
22 In both mammalian models and in human studies, myopia development is associated with rapid
23 scleral thinning and tissue loss.[35-37] Remodelling of the sclera is a major feature in the guinea pig
24 model of myopia in particular.[38] In terms of biomechanics, scleral biomechanical properties varies
25 with the severity of myopia, and focal areas of weakness in the sclera can be found in the myopic
26 eye.[39] Choroidal thinning is closely associated with increasing levels of myopia and MMD[40 41]
27 and in the chicken myopia model, choroid thickness is negatively correlated with myopia.[42] Scleral

1 crosslinking as a means to stop scleral growth has been extensively investigated, but clinical
2 application has been limited by a lack of safe and effective methods for applying ultraviolet A
3 radiation and chemicals to the posterior sclera.[43 44] Lastly, scleral regenerative therapy is an
4 approach whereby human fibroblasts transplanted onto the posterior sclera may strengthen the sclera
5 by producing type I collagen, and has been shown to significantly reduce axial elongation in a rat
6 myopia model.[45]

7

8 Conclusion:

9 There is currently no definitive evidence to suggest that myopia control in childhood could prevent
10 PM development later in life, and as such, long-term prospective studies are needed to answer this
11 question. Research in myopia treatment would benefit from a shift in focus towards devising clinical
12 therapies targeted at preventing AL elongation and PM. However, there is currently insufficient
13 evidence to support a primary site of pathology in PM. Thus research into possible strategic targets
14 for therapies may require focus on multiple sites, as current evidence suggest the possibility of
15 Bruch's membrane, choroid and sclera all playing a role in PM development.

16

17 **Controversy 2: There is currently no “gold standard” intervention in the clinical management** 18 **of myopia control.**

19

20 Atropine eyedrops, orthokeratology, defocus multizone soft contact lens[46] and defocus incorporated
21 multiple segments (DIMS) spectacle lenses[47] have been reported to be effective options for
22 reducing myopia progression. Soft contact lenses and DIMS spectacles are recent innovations that
23 have shown great promise for myopia control. A 3 year randomized clinical trial of MiSight dual
24 focus contact lens (CooperVision, Pleasanton, CA, USA) (n=109) showed that myopia progression
25 and axial elongation were 59% and 52% less in the MiSight arm than the single vision contact lens
26 arm.[46] In the 2 year randomised clinical trial of DIMS spectacles (n=160), children on DIMS
27 spectacles had significantly slower myopia progression and axial elongation (52% and 62%

1 respectively) over 2 years when compared with those wearing single vision spectacle lenses. [48]
2 However, variations between studies and individuals are large in the former and only one study in the
3 later, further studies is warranted. There is also growing interest in combining pharmaceutical and
4 lens based interventions.[49] A recent study (n=60) evaluated the efficacy of atropine 0.01% eyedrops
5 as an adjunctive treatment for children who have already been on ortho-k treatment for a year. While
6 on Ortho-k treatment in the first year, axial elongation was 0.46 ± 0.16 mm/yr, decreasing
7 significantly to 0.14 ± 0.14 mm/yr ($p < 0.001$) when atropine was added in the second year.[50] The
8 potential synergistic effects from combination therapy may be of benefit particularly for rapid myopia
9 progressors

10

11 These treatment options are usually offered to patients based on the expertise of the eye care
12 professional, influenced by a wide range of practice patterns around the world.[6] However, the
13 clinical management of myopia ideally should be evidence-based, selected to provide the best risk-
14 benefit profile for that individual or child. Recently, two interventions have emerged with greatest
15 potential for myopia control:

16 ‘Should orthokeratology be the treatment of choice for controlling myopia progression in children?’

17 Orthokeratology (Ortho-K) has been reported to be effective in controlling myopia progression (30-
18 56% reduction)[51-56] Ortho-K may have different treatment effects depending on the age and degree
19 of myopia. In the Retardation of Myopia in Orthokeratology (ROMIO) study, the effectiveness of
20 ortho-k on myopia control was observed to be better in younger children less than 9 years than in
21 older subjects.[56] In another retrospective study, AL elongation was slower by 49%, 59% and 46%
22 in the low, moderate and high myopia subgroups respectively. While significant differences between
23 orthokeratology and control groups were observed in both the first and second year of follow up in the
24 low and moderate myopia groups, a significant difference was only observed in the first year within
25 the high myopia group.[57] In comparison, atropine’s efficacy depending on concentration, ranges
26 between 60 to 80% reduction.[15-17 58-60]. However, higher doses are associated with increased side
27 effects such as photophobia and a decrease in accommodation amplitude which may result in the need

1 for photochromic, progressive or bifocal addition spectacles. Furthermore there is a need for
2 concurrent spectacle or contact lens usage.[59] On the other hand, the main risk associated with
3 Ortho-K would be infectious keratitis. While the estimated incidence of infectious keratitis in Ortho-K
4 wearers is rare at 7.7/10000 patient eye years, this increases to 13.9/10,000 patient-years in children,
5 which make up the brunt of Ortho-K wear for myopia progression treatment.[61 62] A 10-year
6 retrospective study of 104 eyes of 53 children who underwent orthokeratology treatment observed
7 adverse events in 53 eyes (51%). Of these, conjunctival complications such as allergic conjunctivitis
8 were the most frequent, while corneal infiltration and keratitis occurred in 8 eyes (7.7%).[63] To put
9 the figures in perspective, the estimated incidence of infectious keratitis in daily-wear rigid-gas-
10 permeable (RGP) lens wearers is 1.2/10,000, while in extended wear soft lens wearers, the incidence
11 ranges from 13.3 – 19.5/10,000. This suggests that Ortho-K wear risk in children is essentially similar
12 to that of extended wear soft contact lens wear.[64] Risk factors for infectious keratitis include
13 overnight wear, insufficient training of practitioners and wearers, non-professional fitting procedures,
14 poor compliance with lens hygiene, or inadequate follow-up.[65] These infections can be severe and
15 may result in visual loss or the need for corneal transplantation. Importantly, parents should be
16 counseled as to the risk of infectious keratitis and eye care professionals should undergo rigorous
17 training and accreditation before prescribing Ortho-K to ensure quality control. Besides microbial
18 keratitis, other side effects of Ortho-K include induced astigmatism, third and fourth order spherical
19 aberrations, recurrent corneal erosion, corneal staining, edema and haze.[61 62]

20

21 Rebound upon discontinuation is an important issue emphasized in atropine but this has been less
22 widely studied in Ortho-K.[16 58 66] In terms of vision, Ortho-K provides the best uncorrected visual
23 acuity, whereas atropine may cause poor near visual acuity especially with higher doses and
24 spectacles are still required. Quality of life and subjective ratings from multiple studies show an
25 improvement with Ortho-K compared to wearing single vision spectacles.[67-69] The cost
26 effectiveness of Ortho-K requires further study. Ortho-K lenses in general are more expensive than
27 other optical interventions, costing annually on an average, USD\$1000-2000[70], requiring

1 individualised design and fitting, and intensive review to detect complications. Additionally, they are
2 usually not covered by most health reimbursement or insurance plans.[70]

3

4 ‘Should atropine eye drops be used in children with low or no myopia to prevent myopia
5 progression?’

6 Both the Meta-analysis of Interventions for Myopia Control (30 RCTs, 5,422 eyes) and the Meta-
7 analysis of Atropine Studies for Myopia Control (19 studies, 3,137 children) concluded that atropine
8 markedly slowed myopia progression.[60] [59] While there is currently only one small study
9 providing evidence for the effectiveness of atropine in children with no myopia[71], it is known that
10 younger age of myopia onset is associated with high myopia. It can be safely predicted that 5-year-old
11 children, whose refraction are between +0.75D to -0.49D will soon develop myopia. These may be
12 the at-risk group (pre-myopes) that is likely to benefit from low dose atropine use. ATOM3 is an
13 ongoing double-blind randomized placebo-controlled clinical trial initiated in June 2017 to evaluate
14 the use of atropine 0.01% in the prevention and control of myopia in pre-myopes.[72]

15

16 The main concern against using atropine in children with no myopia is the risk of side effects. In the
17 LAMP study, 30-34% of children on atropine required photochromatic glasses and 2.8-6.4%
18 developed allergic conjunctivitis.[18] 70% and 61% of subjects receiving 0.5% and 0.1% atropine,
19 respectively, requested progressive glasses for reading in the ATOM 2 study.[16] In the LAMP
20 study, even 0.01% atropine was associated with accommodation paralysis in 1.8% of subjects.[18]
21 Hence, some children may paradoxically require spectacles after commencing atropine. Although
22 extremely rare, there is a risk of more severe systemic side effects such as palpitations, confusion, dry
23 mouth and high fever. In addition, the long term side effects of atropine eyedrops are still unclear. In
24 children, a rebound effect was observed upon abrupt cessation of treatment, where the rate of myopia
25 progression increased. When higher atropine was stopped for 12 months after 24 months of treatment
26 (phase 2 of ATOM2), there was a rapid increase in myopia in children originally treated with higher
27 concentrations of atropine, whereas those receiving the lowest concentration of 0.01% showed

1 minimal change.[16 66] This rebound phenomenon can significantly reduce the effectiveness of
2 atropine eyedrops for myopia control, compared to optical treatments. Importantly, atropine is largely
3 used as an off-label treatment for myopia in most countries. Where low dose atropine eyedrops
4 unavailable commercially, the use of low dose atropine may bear significant risks from patients
5 diluting down higher doses and inconsistencies from compounding pharmacies.

6

7 Conclusion:

8 Overall, optimizing the clinical management of myopia would benefit from an alignment of best
9 practice patterns, with a tailored approach that can only be achieved with close collaboration amongst
10 eye care practitioners. While current evidence suggests that low-dose atropine is a good option,
11 potential side-effects and the lack of availability in certain healthcare settings needs to be considered.
12 However, the use of atropine in children with low or no myopia requires further evidence from
13 clinical trials prior to any recommendation. There are other emerging treatment options that are
14 effective such as orthokeratology, contact lens, and spectacles, which should be considered in the
15 holistic management pathway of myopia. Finally, there is growing interest in combining
16 interventions,[49] such as atropine and orthokeratology which may have a synergistic effect while
17 balancing the risks and benefits of both therapies.[50]

18

19

20 **Controversy 3: Current technology is inadequate for the diagnosis and monitoring of myopia**
21 **related complications.**

22

23

24 The burden of visual impairment arising from myopia comes primarily from PM and its complications
25 such as MMD, which is now a leading cause of blindness in developed nations.[73] Thus, the early
26 detection and monitoring for myopia-related complications is important for timely intervention and
27 prevention of visual impairment.[74] The detection and evaluation of two major complications of PM,
28 myopic choroidal neovascularisation and myopia-associated optic neuropathy, are discussed:

29

1 'Is optical coherence tomographic angiography (OCTA) adequate for the evaluation of myopic
2 choroidal neovascularisation?'

3 Optical coherence tomographic angiography (OCTA) is a relatively new imaging technology that has
4 emerged as a potential alternative to more invasive imaging modalities, namely fundus fluorescein
5 angiography (FFA) for the evaluation of myopic choroidal neovascularisation (CNV). The pooled
6 diagnostic accuracy of OCTA was reported in 2 separate meta-analyses to have a sensitivity of 0.87-
7 0.90, specificity of 0.97 and an area under the curve of 0.96 for detecting CNV.[75 76] OCTA, in
8 conjunction with OCT, can be utilized for the monitoring of treatment response and activity. On OCT,
9 the resolution of subretinal hyper-reflective material, subretinal fluid and a well-defined border to the
10 CNV lesion are reliable signs of inactivity. On OCTA, the CNV lesion typically decreases in size
11 although the vascular network persists, regular monitoring of the vascular network size on OCTA is
12 useful for assessing for recurrence.[74]

13

14 However, several limitations of OCTA remain. First, OCTA informs of perfusion through the
15 vascular complex but offers no information on vascular leakage, which is a key treatment indicator.
16 Relying on OCTA alone may result in over-treatment of inactive mCNV. Second, artefacts and poor
17 scan quality are common in patients with poor vision and who are thus unable to sustain fixation long
18 enough for scan acquisition. Third, segmentation errors are particularly prevalent in highly myopic
19 eyes with long axial lengths, steep retinal contours and posterior staphyloma. Moreover, poor fixation
20 and motion artefacts are common causes of uninterpretable scans (**Figure 2**).

21

22 'Can current diagnostics adequately diagnose and monitor glaucoma or myopia-associated optic
23 neuropathy in high myopes?'

24 There are several challenges for the adequate diagnosis and monitoring of glaucoma or myopia-
25 associated optic neuropathy in high myopes. Anatomically, the three layers of the optic nerve head,
26 namely the BM opening, the choroidal opening, and the opening in the peripapillary scleral flange
27 covered by the lamina cribrosa get misaligned by a shift of the BM opening usually into the temporal

1 inferior direction.[77] This leads to an overhanging of BM into the intrapapillary region at the nasal
2 disc border, and to an absence of BM in the temporal parapapillary region, i.e. the temporal gamma
3 zone.[77 78] With an axial length of more than 26.5mm, the BM opening additionally enlarges,
4 eventually leading to a circular gamma zone, In addition, the colour contrast and spatial contrast
5 between the optic cup and neuroretinal rim decrease with longer axial length. This complicates the
6 assessment of cup to disc ratio and measurements of retinal nerve fibre layer (RNFL) thickness with
7 OCT. Functionally, these eyes often have macular pathology and these may confuse the assessment
8 of glaucomatous visual field defects on perimetry. The decreased scleral rigidity in highly myopic
9 eyes may also result in underestimation of the intraocular pressure in these eyes.[79 80]

10

11 Regardless, there are clinical indicators and clues that can aid a physician in diagnosing and
12 monitoring glaucoma in these patients. First, glaucoma is a progressive disease in which longitudinal
13 analysis is key. By comparing the same eye over time, the impact of ambiguous anatomy on diagnosis
14 and monitoring will be reduced. Second, assessing the macular ganglion cell-inner plexiform layer
15 (GC-IPL) thickness measurements in areas without BM defects for vertical asymmetry is also a useful
16 method for diagnosis and monitoring glaucoma because most eyes with MMD tend to have
17 preservation of the inner retinal thickness at least in the earlier stages.[81]

18

19 However, none of the current imaging modalities currently used for glaucoma assessment has been
20 optimized for use in high myopes. RNFL measurements with OCT is problematic due to an indistinct
21 BM edge which tends to shift temporally in high myopes. The superior and inferior RNFL converge
22 more temporally than in a non-highly myopic eye, and signal loss around optic disc can occur in the
23 presence of a posterior staphyloma. GC-IPL measurements can be inaccurate when there is co-
24 existing myopic traction maculopathy (**Figure 3**) or underlying BM defects. An overarching
25 limitation of structural analysis is the lack of a normative database for the highly myopic population,
26 which is likely to differ significantly from a database of non-highly myopic eyes due to the above-
27 mentioned anatomical differences. Lastly, objective visual field assessment such as the Humphrey

1 Visual Field (HVF) is often unable to differentiate between deterioration due to glaucoma or myopic
2 maculopathy.[79 82]

3

4 Conclusion:

5 The structure of the myopic eye adds complexity to the evaluation and early detection of sight
6 threatening complications such as MMD and myopia-associated optic neuropathy, that cannot be
7 bridged with current diagnostics. Collaboration between clinicians, researchers and industry is needed
8 to optimize diagnostic and imaging technologies specifically for the myopic eye. Currently, OCTA
9 imaging alone may be inadequate for evaluating myopic CNV, while the evaluation of myopia-
10 associated optic neuropathy requires further research to accurately evaluate optic nerve damage in
11 PM. Overall, there is an unmet need to explore and develop new imaging modalities for both
12 structural and functional analyses and to establish normative databases for myopia in the long term.

13

14 **Summary and Conclusions**

15 The aim of this review is to highlight various aspects of clinical myopia discussed during the
16 International Myopia Summit in 2019, including gaps in myopia research that require further study,
17 consensus where evidence is not well established, and a call to action for stakeholders to collaborate
18 in the management of myopia. We acknowledge that the views presented are limited to that of the
19 workgroup, which comprised an international panel from diverse backgrounds, all involved in myopia
20 prevention or research. There are also potential biases arising from the representation of myopia
21 experts mainly from Asia, but we have included a comprehensive review of the available published
22 evidence to provide an objective summary in this article. Nonetheless, we have highlighted three key
23 areas with regards to the clinical management of myopia, which may benefit from further research
24 and development. First, controlling childhood myopia is theoretically preventing further high myopia
25 in adulthood. However, as controlling childhood myopia alone may not be enough to prevent the
26 development of PM in adulthood, there is an unmet need to search for potential treatment targets and
27 to develop therapies interventions that prevent progression to PM. Second, the clinical management of

1 myopia will benefit from co-management from eye care professionals, such that the treatment plan
 2 may be tailored to patient needs while weighing the relative costs and benefits of each intervention.
 3 Third, evaluation of myopia complications using current technologies present limitations that require
 4 collaboration between clinicians, researchers and industry partners to overcome in the long term. The
 5 workgroup advocated a paradigm shift in our approach to clinical management of myopia - one that
 6 necessitates coordinated action among the eye care community in our fight against the ‘myopia
 7 epidemic’.

8
 9

10 Supplementary Table 1: A summary of debated topics and consensus achieved at the International
 11 Myopia Summit

12

Motion	Consensus
Myopia Prevention and Public Policy	
Are current myopia definitions to inform public policy currently adequate?	There is overemphasis on cut-off values for myopia. Myopia as a refractive error is a continuous measure with multifactorial risk for developing complications.[12 83]
Should myopia be a primary priority for health ministries in Asia?	Advocates require more data on cost effectiveness and societal impact, (which includes workforce productivity, education and national defense), to justify and empower ministries to act.[84-96]
Should outdoor time be mandated for all school-going children?	This is considered the most cost-effective myopia prevention strategy, but there are challenges in its implementation. There is a need to engage stakeholders, such as parents, health and

	education ministries to address these challenges.[87 97-100]
Myopia Control	
Should “breaks” in near work activities be mandated for all school-going children?	More evidence is needed to support this intervention. The causal relationship between myopia and near work, the relative contribution of near work vs outdoor activity, and the effect of different types of near work on myopia require further study.[101-107]
Is orthokeratology the treatment of choice for controlling myopia progression in children?	Careful patient selection and stringent follow up with close co-management between optometrists and ophthalmologists are important to maximize efficacy and minimize the risk of blinding complications.[51-61 63-70]
Should atropine be used in children with low or no myopia to prevent myopia progression?	Low dose atropine is effective for myopia control in children with low myopia, but the exact dosage to minimise side effects whilst retaining efficacy is still to be determined. Further evidence from clinical trials for the safety and efficacy of low dose atropine in children without myopia is needed.[16 18 59 60 66 71]
Myopia myths	
Are environmental factors more important than genetics as a determinant of myopia?	The effectiveness of environmental interventions should be considered in the context of different genetic risk determinants.[108-112]
Are near work and increased screen time related to myopia progression?	Near work is related to myopia onset and progression, but this is less clear for increased

	<p>screen time. More studies are needed to investigate the effect of increased screen time on increased near work and reduced time spent outdoors.[98 102 113 114]</p>
<p>Does controlling myopia in childhood prevent pathologic myopia in adulthood?</p>	<p>Pathologic myopia is a multifactorial disease with additional risk factors besides refractive error, such as age, gender and genetics. Controlling refractive error alone may not be enough to prevent pathologic myopia. Long term studies are needed to assess the effectiveness of myopia control in childhood on the prevention of pathologic myopia in adulthood.[10-27]</p>
<p>Industry and regulation of myopia treatment</p>	
<p>Should spectacles be reimbursed by health insurance and/or public health care providers?</p>	<p>WHO has included spectacles in the list of Priority Assistive Products, and spectacle coverage is now an indicator for Universal Health Coverage. However, there are barriers to implementation that need to be overcome, including the lack of integration of refractive and optical services in health systems, regulatory hurdles and issues of equitability.[115]</p>
<p>Should orthokeratology be regulated as a medical device?</p>	<p>Orthokeratology is regulated as a medical device by many government agencies. More stringent regulations may be required, such as a requirement for eyecare professionals to be trained and certified before they can prescribe orthokeratology. Co-management between</p>

	<p>optometrists and ophthalmologists is important to minimize the risk of complications such as corneal infections.[62 116 117]</p>
<p>Should refractive surgery be considered a medical treatment for adult high myopia?</p>	<p>Refractive surgery should not be considered a medical treatment because of issues with efficacy and predictability of excimer laser treatments, side effects of phakic intraocular lenses, risk of malpractice litigation and lack of evidence for cost effectiveness compared to spectacles or contact lenses.[118-122]</p>
<p>Pathologic myopia</p>	
<p>Is wide field imaging mandatory to screen for pathologic myopia in adult high myopes?</p>	<p>The cost, affordability, quality and accuracy of wide field imaging requires further study. Wide field imaging cannot replace good history taking and a dilated fundal examination. Guidelines on who to screen and what to screen for are needed.[123 124]</p>
<p>Is retinal detachment in high myopes best managed with combined scleral buckling and vitrectomy?</p>	<p>High myopes with rhegmatogenous retinal detachment are typically younger, phakic patients that can be adequately managed with scleral buckling alone. In more complex cases requiring vitrectomy, adding an encircling scleral buckle to support the vitreous base may optimise single surgery success rates.[125-128]</p>
<p>Should myopic traction maculopathy be treated early before vision deteriorates?</p>	<p>There is significant risk of visual loss from macular hole associated with surgery for myopic traction maculopathy. Surgery should be reserved</p>

	for patients with foveal detachment or worsening vision, and monitoring is advised for patients with early stages of myopic traction maculopathy.[129-133]
Is optical coherence tomographic angiography adequate for starting treatment in and monitoring of myopic choroidal neovascularisation?	The structural abnormalities of the highly myopic eye present significant difficulty for current imaging technology, including optical coherence tomographic angiography. Collaboration between clinicians, researchers and industry partners is needed to improve and optimize imaging modalities for the myopic eye.[74-76]
Is Bruch's membrane the primary site of pathology in pathologic myopia?	There is insufficient evidence to support a primary site of pathology in pathologic myopia. Further research is required to elucidate the pathogenesis to guide the development interventions for pathologic myopia.[28-32 35-42]
Can glaucoma in high myopes be adequately diagnosed and monitored with current diagnostics?	There is a need to explore and develop other new imaging modalities and to build normative databases for both structural and functional analyses. This requires close collaboration between clinicians, researchers and industry partners.[79-82]

1

2

3 Supplementary table 2: Organisations represented at the International Myopia Summit Workgroup

4 2019.

Organisations	<ol style="list-style-type: none"> 1. World Health Organisation (Western Pacific Region) 2. International Agency for Prevention of Blindness 3. International Myopia Institute 4. World Optometry Council 5. Centre for Eye Research Australia, Australia 6. Brien Holden Vision Institute, Australia 7. School of Optometry and Vision Science, University of New South Wales 8. School of Optometry and Vision Science, Queensland University of Technology, Australia 9. Research School of Biology, Australian National University, Australia 10. Shanghai Eye Diseases Prevention & Treatment Centre, China 11. Department of Ophthalmology, Wenzhou Medical College, China 12. Medical Faculty Mannheim, Heidelberg University, Germany 13. Singapore Eye Research Institute, Singapore 14. National University Hospital, Singapore 15. National Healthcare Group Eye Institute, Singapore 16. Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 17. Kaohsiung Chang Gung Memorial Hospital, Chinese Taipei 18. Chang Gung University College of Medicine, Chinese Taipei 19. International Centre for Eye Health, London School of Hygiene and Tropical Medicine, United Kingdom 20. Department of Ophthalmology, Columbia University, USA
---------------	---

1
2
3
4
5

References

- 1 1. Wu LJ, You QS, Duan JL, et al. Prevalence and associated factors of myopia in high-
2 school students in Beijing. *PloS one* 2015;**10**(3):e0120764 doi:
3 10.1371/journal.pone.0120764[published Online First: Epub Date]].
- 4 2. Wu JF, Bi HS, Wang SM, et al. Refractive error, visual acuity and causes of vision loss in
5 children in Shandong, China. The Shandong Children Eye Study. *PloS one*
6 2013;**8**(12):e82763 doi: 10.1371/journal.pone.0082763[published Online First: Epub
7 Date]].
- 8 3. Jung SK, Lee JH, Kakizaki H, Jee D. Prevalence of myopia and its association with body
9 stature and educational level in 19-year-old male conscripts in seoul, South Korea.
10 *Investigative ophthalmology & visual science* 2012;**53**(9):5579-83 doi:
11 10.1167/iovs.12-10106[published Online First: Epub Date]].
- 12 4. Matsumura H, Hirai H. Prevalence of myopia and refractive changes in students from 3 to
13 17 years of age. *Surv Ophthalmol* 1999;**44 Suppl 1**:S109-15
- 14 5. Wu HM, Seet B, Yap EP, Saw SM, Lim TH, Chia KS. Does education explain ethnic
15 differences in myopia prevalence? A population-based study of young adult males in
16 Singapore. *Optometry and vision science : official publication of the American*
17 *Academy of Optometry* 2001;**78**(4):234-9
- 18 6. Ang M, Flanagan JL, Wong CW, et al. Review: Myopia control strategies
19 recommendations from the 2018 WHO/IAPB/BHVI Meeting on Myopia. *Br J*
20 *Ophthalmol* 2020 doi: 10.1136/bjophthalmol-2019-315575[published Online First:
21 Epub Date]].
- 22 7. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. *Lancet* 2012;**379**(9827):1739-48 doi:
23 10.1016/S0140-6736(12)60272-4[published Online First: Epub Date]].
- 24 8. Flitcroft DI, He M, Jonas JB, et al. IMI - Defining and Classifying Myopia: A Proposed
25 Set of Standards for Clinical and Epidemiologic Studies. *Investigative ophthalmology*
26 *& visual science* 2019;**60**(3):M20-M30 doi: 10.1167/iovs.18-25957[published Online
27 First: Epub Date]].
- 28 9. World Health Organization - Brien Holden Vision Institute. The impact of myopia. The
29 Impact of Myopia and High Myopia. Report of the Joint World Health Organization–
30 Brien Holden Vision Institute Global Scientific Meeting on Myopia.
- 31 10. Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. *Prog Retin*
32 *Eye Res* 2016;**52**:156-87 doi: 10.1016/j.preteyeres.2015.12.001[published Online
33 First: Epub Date]].
- 34 11. Ohno-Matsui K, Jonas JB. Posterior staphyloma in pathologic myopia. *Prog Retin Eye*
35 *Res* 2019;**70**:99-109 doi: 10.1016/j.preteyeres.2018.12.001[published Online First:
36 Epub Date]].
- 37 12. Wong YL, Sabanayagam C, Ding Y, et al. Prevalence, Risk Factors, and Impact of
38 Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults
39 in Singapore. *Investigative ophthalmology & visual science* 2018;**59**(11):4603-13 doi:
40 10.1167/iovs.18-24032[published Online First: Epub Date]].

- 1 13. Chen Y, Zhang J, Morgan IG, He M. Identifying Children at Risk of High Myopia Using
2 Population Centile Curves of Refraction. *PloS one* 2016;**11**(12):e0167642 doi:
3 10.1371/journal.pone.0167642[published Online First: Epub Date]].
- 4 14. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. *Optometry*
5 and vision science : official publication of the American Academy of Optometry
6 2019;**96**(6):463-65 doi: 10.1097/OPX.0000000000001367[published Online First:
7 Epub Date]].
- 8 15. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia:
9 safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of
10 Myopia 2). *Ophthalmology* 2012;**119**(2):347-54 doi:
11 10.1016/j.ophtha.2011.07.031[published Online First: Epub Date]].
- 12 16. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia
13 2: Myopia Control with Atropine 0.01% Eyedrops. *Ophthalmology* 2016;**123**(2):391-
14 9 doi: 10.1016/j.ophtha.2015.07.004[published Online First: Epub Date]].
- 15 17. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood
16 myopia. *Ophthalmology* 2006;**113**(12):2285-91 doi:
17 10.1016/j.ophtha.2006.05.062[published Online First: Epub Date]].
- 18 18. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression
19 (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%,
20 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. *Ophthalmology*
21 2019;**126**(1):113-24 doi: 10.1016/j.ophtha.2018.05.029[published Online First: Epub
22 Date]].
- 23 19. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration
24 Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. *Ophthalmology*
25 2019 doi: 10.1016/j.ophtha.2019.12.011[published Online First: Epub Date]].
- 26 20. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. *Am J*
27 *Ophthalmol* 1997;**123**(2):181-7 doi: 10.1016/s0002-9394(14)71034-7[published
28 Online First: Epub Date]].
- 29 21. Kobayashi K, Ohno-Matsui K, Kojima A, et al. Fundus characteristics of high myopia in
30 children. *Jpn J Ophthalmol* 2005;**49**(4):306-11 doi: 10.1007/s10384-004-0204-
31 6[published Online First: Epub Date]].
- 32 22. Hsiang HW, Ohno-Matsui K, Shimada N, et al. Clinical characteristics of posterior
33 staphyloma in eyes with pathologic myopia. *Am J Ophthalmol* 2008;**146**(1):102-10
34 doi: 10.1016/j.ajo.2008.03.010[published Online First: Epub Date]].
- 35 23. Lim LS, Saw SM, Jeganathan VS, et al. Distribution and determinants of ocular biometric
36 parameters in an Asian population: the Singapore Malay eye study. *Investigative*
37 *ophthalmology & visual science* 2010;**51**(1):103-9 doi: 10.1167/iovs.09-
38 3553[published Online First: Epub Date]].
- 39 24. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term results of photodynamic
40 therapy for choroidal neovascularization in Japanese patients with pathologic myopia.

- 1 Am J Ophthalmol 2011;**151**(1):137-47 e1 doi: 10.1016/j.ajo.2010.06.046[published
2 Online First: Epub Date]].
- 3 25. Hashimoto S, Yasuda M, Fujiwara K, et al. Association between Axial Length and
4 Myopic Maculopathy: The Hisayama Study. *Ophthalmol Retina* 2019;**3**(10):867-73
5 doi: 10.1016/j.oret.2019.04.023[published Online First: Epub Date]].
- 6 26. Li YJ, Guggenheim JA, Bulusu A, et al. An international collaborative family-based
7 whole-genome linkage scan for high-grade myopia. *Investigative ophthalmology &
8 visual science* 2009;**50**(7):3116-27 doi: 10.1167/iovs.08-2781[published Online First:
9 Epub Date]].
- 10 27. Wong YL, Hysi P, Cheung G, et al. Genetic variants linked to myopic macular
11 degeneration in persons with high myopia: CREAM Consortium. *PloS one*
12 2019;**14**(8):e0220143 doi: 10.1371/journal.pone.0220143[published Online First:
13 Epub Date]].
- 14 28. Jonas JB, Panda-Jonas S. Secondary Bruch's membrane defects and scleral staphyloma in
15 toxoplasmosis. *Acta Ophthalmol* 2016;**94**(7):e664-e66 doi:
16 10.1111/aos.13027[published Online First: Epub Date]].
- 17 29. Jonas JB, Holbach L, Panda-Jonas S. Histologic differences between primary high
18 myopia and secondary high myopia due to congenital glaucoma. *Acta Ophthalmol*
19 2016;**94**(2):147-53 doi: 10.1111/aos.12937[published Online First: Epub Date]].
- 20 30. Jonas JB, Ohno-Matsui K, Jiang WJ, Panda-Jonas S. BRUCH MEMBRANE AND THE
21 MECHANISM OF MYOPIZATION: A New Theory. *Retina* 2017;**37**(8):1428-40 doi:
22 10.1097/IAE.0000000000001464[published Online First: Epub Date]].
- 23 31. Dong L, Shi XH, Kang YK, et al. Bruch's Membrane Thickness and Retinal Pigment
24 Epithelium Cell Density in Experimental Axial Elongation. *Sci Rep* 2019;**9**(1):6621
25 doi: 10.1038/s41598-019-43212-8[published Online First: Epub Date]].
- 26 32. Jonas JB, Ohno-Matsui K, Holbach L, Panda-Jonas S. Retinal pigment epithelium cell
27 density in relationship to axial length in human eyes. *Acta Ophthalmol*
28 2017;**95**(1):e22-e28 doi: 10.1111/aos.13188[published Online First: Epub Date]].
- 29 33. Dong L, Shi XH, Kang YK, et al. Amphiregulin and ocular axial length. *Acta Ophthalmol*
30 2019;**97**(3):e460-e70 doi: 10.1111/aos.14080[published Online First: Epub Date]].
- 31 34. Jiang WJ, Song HX, Li SY, et al. Amphiregulin Antibody and Reduction of Axial
32 Elongation in Experimental Myopia. *EBioMedicine* 2017;**17**:134-44 doi:
33 10.1016/j.ebiom.2017.02.021[published Online First: Epub Date]].
- 34 35. McBrien NA, Lawlor P, Gentle A. Scleral remodeling during the development of and
35 recovery from axial myopia in the tree shrew. *Investigative ophthalmology & visual
36 science* 2000;**41**(12):3713-9
- 37 36. Norton TT, Rada JA. Reduced extracellular matrix in mammalian sclera with induced
38 myopia. *Vision Res* 1995;**35**(9):1271-81 doi: 10.1016/0042-6989(94)00243-
39 f[published Online First: Epub Date]].

- 1 37. Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia.
2 An electron microscopic study. Arch Ophthalmol 1979;**97**(5):912-5 doi:
3 10.1001/archopht.1979.01020010470017[published Online First: Epub Date]].
- 4 38. Tian XD, Cheng YX, Liu GB, et al. Expressions of type I collagen, alpha2 integrin and
5 beta1 integrin in sclera of guinea pig with defocus myopia and inhibitory effects of
6 bFGF on the formation of myopia. Int J Ophthalmol 2013;**6**(1):54-8 doi:
7 10.3980/j.issn.2222-3959.2013.01.11[published Online First: Epub Date]].
- 8 39. Hoang QV, Rohrbach D, McFadden SA, Mamou J. Regional changes in the elastic
9 properties of myopic Guinea pig sclera. Exp Eye Res 2019;**186**:107739 doi:
10 10.1016/j.exer.2019.107739[published Online First: Epub Date]].
- 11 40. Wei WB, Xu L, Jonas JB, et al. Subfoveal choroidal thickness: the Beijing Eye Study.
12 Ophthalmology 2013;**120**(1):175-80 doi: 10.1016/j.ophtha.2012.07.048[published
13 Online First: Epub Date]].
- 14 41. Wong CW, Phua V, Lee SY, Wong TY, Cheung CM. Is Choroidal or Scleral Thickness
15 Related to Myopic Macular Degeneration? Investigative ophthalmology & visual
16 science 2017;**58**(2):907-13 doi: 10.1167/iovs.16-20742[published Online First: Epub
17 Date]].
- 18 42. Nickla DL, Totonelly K. Choroidal thickness predicts ocular growth in normal chicks but
19 not in eyes with experimentally altered growth. Clin Exp Optom 2015;**98**(6):564-70
20 doi: 10.1111/cxo.12317[published Online First: Epub Date]].
- 21 43. Dotan A, Kremer I, Gal-Or O, et al. Scleral Cross-linking Using Riboflavin and
22 Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model. J Vis Exp
23 2016(110):e53201 doi: 10.3791/53201[published Online First: Epub Date]].
- 24 44. Liu S, Li S, Wang B, et al. Scleral Cross-Linking Using Riboflavin UVA Irradiation for
25 the Prevention of Myopia Progression in a Guinea Pig Model: Blocked Axial
26 Extension and Altered Scleral Microstructure. PloS one 2016;**11**(11):e0165792 doi:
27 10.1371/journal.pone.0165792[published Online First: Epub Date]].
- 28 45. Shinohara K, Yoshida T, Liu H, et al. Establishment of novel therapy to reduce
29 progression of myopia in rats with experimental myopia by fibroblast transplantation
30 on sclera. J Tissue Eng Regen Med 2018;**12**(1):e451-e61 doi:
31 10.1002/term.2275[published Online First: Epub Date]].
- 32 46. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year
33 Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optometry and
34 vision science : official publication of the American Academy of Optometry
35 2019;**96**(8):556-67 doi: 10.1097/OPX.0000000000001410[published Online First:
36 Epub Date]].
- 37 47. Lam CSY TW, Lee PK, et al Lam CSY, Tang WC, Lee PK, et al (2017) Myopic control
38 with multi-segment of myopic defocus (MSMD) spectacle lens: A randomized
39 clinical trial. Birmingham, UK. 2017
- 40 48. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS)
41 spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J

- 1 Ophthalmol 2020;**104**(3):363-68 doi: 10.1136/bjophthalmol-2018-313739[published
2 Online First: Epub Date]].
- 3 49. Shih YF, Hsiao CK, Chen CJ, Chang CW, Hung PT, Lin LL. An intervention trial on
4 efficacy of atropine and multi-focal glasses in controlling myopic progression. *Acta*
5 *Ophthalmol Scand* 2001;**79**(3):233-6 doi: 10.1034/j.1600-
6 0420.2001.790304.x[published Online First: Epub Date]].
- 7 50. Chen Z, Huang S, Zhou J, Xiaomei Q, Zhou X, Xue F. Adjunctive effect of
8 orthokeratology and low dose atropine on axial elongation in fast-progressing myopic
9 children-A preliminary retrospective study. *Cont Lens Anterior Eye* 2019;**42**(4):439-
10 42 doi: 10.1016/j.clae.2018.10.026[published Online First: Epub Date]].
- 11 51. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight
12 orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up
13 study. *Investigative ophthalmology & visual science* 2012;**53**(7):3913-9 doi:
14 10.1167/iovs.11-8453[published Online First: Epub Date]].
- 15 52. Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial
16 elongation in childhood myopia. *Investigative ophthalmology & visual science*
17 2011;**52**(5):2170-4 doi: 10.1167/iovs.10-5485[published Online First: Epub Date]].
- 18 53. Lee YC, Wang JH, Chiu CJ. Effect of Orthokeratology on myopia progression: twelve-
19 year results of a retrospective cohort study. *BMC Ophthalmol* 2017;**17**(1):243 doi:
20 10.1186/s12886-017-0639-4[published Online First: Epub Date]].
- 21 54. Sun Y, Xu F, Zhang T, et al. Orthokeratology to control myopia progression: a meta-
22 analysis. *PloS one* 2015;**10**(4):e0124535 doi:
23 10.1371/journal.pone.0124535[published Online First: Epub Date]].
- 24 55. Wen D, Huang J, Chen H, et al. Efficacy and Acceptability of Orthokeratology for
25 Slowing Myopic Progression in Children: A Systematic Review and Meta-Analysis. *J*
26 *Ophthalmol* 2015;**2015**:360806 doi: 10.1155/2015/360806[published Online First:
27 Epub Date]].
- 28 56. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year
29 randomized clinical trial. *Investigative ophthalmology & visual science*
30 2012;**53**(11):7077-85 doi: 10.1167/iovs.12-10565[published Online First: Epub
31 Date]].
- 32 57. Zhu MJ, Feng HY, He XG, Zou HD, Zhu JF. The control effect of orthokeratology on
33 axial length elongation in Chinese children with myopia. *BMC Ophthalmol*
34 2014;**14**:141 doi: 10.1186/1471-2415-14-141[published Online First: Epub Date]].
- 35 58. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of
36 childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. *Am J*
37 *Ophthalmol* 2014;**157**(2):451-57 e1 doi: 10.1016/j.ajo.2013.09.020[published Online
38 First: Epub Date]].
- 39 59. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in
40 Childhood Myopia: A Meta-analysis. *JAMA Ophthalmol* 2017;**135**(6):624-30 doi:
41 10.1001/jamaophthalmol.2017.1091[published Online First: Epub Date]].

- 1 60. Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia
2 Control in Children: A Network Meta-analysis. *Ophthalmology* 2016;**123**(4):697-708
3 doi: 10.1016/j.ophtha.2015.11.010[published Online First: Epub Date]].
- 4 61. Liu YM, Xie P. The Safety of Orthokeratology--A Systematic Review. *Eye Contact Lens*
5 2016;**42**(1):35-42 doi: 10.1097/ICL.0000000000000219[published Online First: Epub
6 Date]].
- 7 62. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with
8 overnight corneal reshaping lenses. *Optometry and vision science : official*
9 *publication of the American Academy of Optometry* 2013;**90**(9):937-44 doi:
10 10.1097/OPX.0b013e31829cac92[published Online First: Epub Date]].
- 11 63. Hiraoka T, Sekine Y, Okamoto F, Mihashi T, Oshika T. Safety and efficacy following 10-
12 years of overnight orthokeratology for myopia control. *Ophthalmic Physiol Opt*
13 2018;**38**(3):281-89 doi: 10.1111/opo.12460[published Online First: Epub Date]].
- 14 64. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related microbial
15 keratitis in Australia. *Ophthalmology* 2008;**115**(10):1655-62 doi:
16 10.1016/j.ophtha.2008.04.002[published Online First: Epub Date]].
- 17 65. VanderVeen DK, Kraker RT, Pineles SL, et al. Use of Orthokeratology for the Prevention
18 of Myopic Progression in Children: A Report by the American Academy of
19 Ophthalmology. *Ophthalmology* 2019;**126**(4):623-36 doi:
20 10.1016/j.ophtha.2018.11.026[published Online First: Epub Date]].
- 21 66. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of
22 childhood myopia: effect on myopia progression after cessation of atropine.
23 *Ophthalmology* 2009;**116**(3):572-9 doi: 10.1016/j.ophtha.2008.10.020[published
24 Online First: Epub Date]].
- 25 67. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Myopia
26 control with orthokeratology contact lenses in Spain: a comparison of vision-related
27 quality-of-life measures between orthokeratology contact lenses and single-vision
28 spectacles. *Eye Contact Lens* 2013;**39**(2):153-7 doi:
29 10.1097/ICL.0b013e31827a0241[published Online First: Epub Date]].
- 30 68. Zhao F, Zhao G, Zhao Z. Investigation of the Effect of Orthokeratology Lenses on
31 Quality of Life and Behaviors of Children. *Eye Contact Lens* 2018;**44**(5):335-38 doi:
32 10.1097/ICL.0000000000000529[published Online First: Epub Date]].
- 33 69. Queiros A, Villa-Collar C, Gutierrez AR, Jorge J, Gonzalez-Meijome JM. Quality of life
34 of myopic subjects with different methods of visual correction using the NEI RQL-42
35 questionnaire. *Eye Contact Lens* 2012;**38**(2):116-21 doi:
36 10.1097/ICL.0b013e3182480e97[published Online First: Epub Date]].
- 37 70. Li X, Friedman IB, Medow NB, Zhang C. Update on Orthokeratology in Managing
38 Progressive Myopia in Children: Efficacy, Mechanisms, and Concerns. *J Pediatr*
39 *Ophthalmol Strabismus* 2017;**54**(3):142-48 doi: 10.3928/01913913-20170106-
40 01[published Online First: Epub Date]].

- 1 71. Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine
2 in premyopic children. *Journal of ocular pharmacology and therapeutics : the official*
3 *journal of the Association for Ocular Pharmacology and Therapeutics*
4 2010;**26**(4):341-5 doi: 10.1089/jop.2009.0135[published Online First: Epub Date]].
- 5 72. Del Amo EM, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug
6 delivery. *Prog Retin Eye Res* 2017;**57**:134-85 doi:
7 10.1016/j.preteyeres.2016.12.001[published Online First: Epub Date]].
- 8 73. Fricke TR, Jong M, Naidoo KS, et al. Global prevalence of visual impairment associated
9 with myopic macular degeneration and temporal trends from 2000 through 2050:
10 systematic review, meta-analysis and modelling. *Br J Ophthalmol* 2018;**102**(7):855-
11 62 doi: 10.1136/bjophthalmol-2017-311266[published Online First: Epub Date]].
- 12 74. Ang M, Wong CW, Hoang QV, et al. Imaging in myopia: potential biomarkers, current
13 challenges and future developments. *Br J Ophthalmol* 2019;**103**(6):855-62 doi:
14 10.1136/bjophthalmol-2018-312866[published Online First: Epub Date]].
- 15 75. Wang R, Liang Z, Liu X. Diagnostic accuracy of optical coherence tomography
16 angiography for choroidal neovascularization: a systematic review and meta-analysis.
17 *BMC Ophthalmol* 2019;**19**(1):162 doi: 10.1186/s12886-019-1163-5[published Online
18 First: Epub Date]].
- 19 76. Faes L, Bodmer NS, Locher S, et al. Test performance of optical coherence tomography
20 angiography in detecting retinal diseases: a systematic review and meta-analysis. *Eye*
21 (Lond) 2019;**33**(8):1327-38 doi: 10.1038/s41433-019-0421-3[published Online First:
22 Epub Date]].
- 23 77. Jonas JB, Ohno-Matsui K, Panda-Jonas S. Optic Nerve Head Histopathology in High
24 Axial Myopia. *J Glaucoma* 2017;**26**(2):187-93 doi:
25 10.1097/IJG.0000000000000574[published Online First: Epub Date]].
- 26 78. Jonas JB, Fang Y, Weber P, Ohno-Matsui K. Parapapillary Gamma and Delta Zones in
27 High Myopia. *Retina* 2018;**38**(5):931-38 doi:
28 10.1097/IAE.0000000000001650[published Online First: Epub Date]].
- 29 79. Tan NYQ, Sng CCA, Ang M. Myopic optic disc changes and its role in glaucoma. *Curr*
30 *Opin Ophthalmol* 2019;**30**(2):89-96 doi: 10.1097/ICU.0000000000000548[published
31 Online First: Epub Date]].
- 32 80. Jonas JB, Nagaoka N, Fang YX, Weber P, Ohno-Matsui K. Intraocular Pressure and
33 Glaucomatous Optic Neuropathy in High Myopia. *Investigative ophthalmology &*
34 *visual science* 2017;**58**(13):5897-906 doi: 10.1167/iovs.17-21942[published Online
35 First: Epub Date]].
- 36 81. Seol BR, Jeoung JW, Park KH. Glaucoma Detection Ability of Macular Ganglion Cell-
37 Inner Plexiform Layer Thickness in Myopic Preperimetric Glaucoma. *Investigative*
38 *ophthalmology & visual science* 2015;**56**(13):8306-13 doi: 10.1167/iovs.15-
39 18141[published Online First: Epub Date]].

- 1 82. Chang RT, Singh K. Myopia and glaucoma: diagnostic and therapeutic challenges. *Curr*
2 *Opin Ophthalmol* 2013;**24**(2):96-101 doi: 10.1097/ICU.0b013e32835cef31[published
3 Online First: Epub Date]].
- 4 83. Luo HD, Gazzard G, Liang Y, Shankar A, Tan DT, Saw SM. Defining myopia using
5 refractive error and uncorrected logMAR visual acuity >0.3 from 1334 Singapore
6 school children ages 7-9 years. *Br J Ophthalmol* 2006;**90**(3):362-6 doi:
7 10.1136/bjo.2005.079657[published Online First: Epub Date]].
- 8 84. Baltussen R, Naus J, Limburg H. Cost-effectiveness of screening and correcting
9 refractive errors in school children in Africa, Asia, America and Europe. *Health*
10 *Policy* 2009;**89**(2):201-15 doi: 10.1016/j.healthpol.2008.06.003[published Online
11 First: Epub Date]].
- 12 85. Congdon N, Zheng M, Sharma A, et al. Prevalence and determinants of spectacle
13 nonwear among rural Chinese secondary schoolchildren: the Xichang Pediatric
14 Refractive Error Study Report 3. *Arch Ophthalmol* 2008;**126**(12):1717-23 doi:
15 10.1001/archopht.126.12.1717[published Online First: Epub Date]].
- 16 86. Fu Y, Geng D, Liu H, Che H. Myopia and/or longer axial length are protective against
17 diabetic retinopathy: a meta-analysis. *Acta Ophthalmol* 2016;**94**(4):346-52 doi:
18 10.1111/aos.12908[published Online First: Epub Date]].
- 19 87. He M, Xiang F, Zeng Y, et al. Effect of Time Spent Outdoors at School on the
20 Development of Myopia Among Children in China: A Randomized Clinical Trial.
21 *JAMA* 2015;**314**(11):1142-8 doi: 10.1001/jama.2015.10803[published Online First:
22 Epub Date]].
- 23 88. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia
24 and Temporal Trends from 2000 through 2050. *Ophthalmology* 2016;**123**(5):1036-42
25 doi: 10.1016/j.opthta.2016.01.006[published Online First: Epub Date]].
- 26 89. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese
27 schoolchildren: 1983 to 2000. *Ann Acad Med Singapore* 2004;**33**(1):27-33
- 28 90. Ma X, Zhou Z, Yi H, et al. Effect of providing free glasses on children's educational
29 outcomes in China: cluster randomized controlled trial. *BMJ* 2014;**349**:g5740 doi:
30 10.1136/bmj.g5740[published Online First: Epub Date]].
- 31 91. Morgan IG, Rose KA, Ellwein LB, Refractive Error Study in Children Survey G. Is
32 emmetropia the natural endpoint for human refractive development? An analysis of
33 population-based data from the refractive error study in children (RESC). *Acta*
34 *Ophthalmol* 2010;**88**(8):877-84 doi: 10.1111/j.1755-3768.2009.01800.x[published
35 Online First: Epub Date]].
- 36 92. Naidoo KS, Fricke TR, Frick KD, et al. Potential Lost Productivity Resulting from the
37 Global Burden of Myopia: Systematic Review, Meta-analysis, and Modeling.
38 *Ophthalmology* 2018 doi: 10.1016/j.opthta.2018.10.029[published Online First: Epub
39 Date]].
- 40 93. Pan CW, Cheung CY, Aung T, et al. Differential associations of myopia with major age-
41 related eye diseases: the Singapore Indian Eye Study. *Ophthalmology*

- 1 2013;**120**(2):284-91 doi: 10.1016/j.ophtha.2012.07.065[published Online First: Epub
2 Date]].
- 3 94. Wang SK, Guo Y, Liao C, et al. Incidence of and Factors Associated With Myopia and
4 High Myopia in Chinese Children, Based on Refraction Without Cycloplegia. *JAMA*
5 *Ophthalmol* 2018;**136**(9):1017-24 doi: 10.1001/jamaophthalmol.2018.2658[published
6 Online First: Epub Date]].
- 7 95. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden
8 of pathologic myopia and myopic choroidal neovascularization: an evidence-based
9 systematic review. *Am J Ophthalmol* 2014;**157**(1):9-25 e12 doi:
10 10.1016/j.ajo.2013.08.010[published Online First: Epub Date]].
- 11 96. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine
12 use in myopia control. *Eye (Lond)* 2019;**33**(1):3-13 doi: 10.1038/s41433-018-0139-
13 7[published Online First: Epub Date]].
- 14 97. Cao K, Wan Y, Yusufu M, Wang N. Significance of Outdoor Time for Myopia
15 Prevention: A Systematic Review and Meta-Analysis Based on Randomized
16 Controlled Trials. *Ophthalmic Res* 2019:1-9 doi: 10.1159/000501937[published
17 Online First: Epub Date]].
- 18 98. Guan H, Yu NN, Wang H, et al. Impact of various types of near work and time spent
19 outdoors at different times of day on visual acuity and refractive error among Chinese
20 school-going children. *PloS one* 2019;**14**(4):e0215827 doi:
21 10.1371/journal.pone.0215827[published Online First: Epub Date]].
- 22 99. Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: Aetiology and
23 prevention. *Prog Retin Eye Res* 2018;**62**:134-49 doi:
24 10.1016/j.preteyeres.2017.09.004[published Online First: Epub Date]].
- 25 100. Wu PC, Chen CT, Lin KK, et al. Myopia Prevention and Outdoor Light Intensity in a
26 School-Based Cluster Randomized Trial. *Ophthalmology* 2018;**125**(8):1239-50 doi:
27 10.1016/j.ophtha.2017.12.011[published Online First: Epub Date]].
- 28 101. Gifford KL, Richdale K, Kang P, et al. IMI - Clinical Management Guidelines Report.
29 *Investigative ophthalmology & visual science* 2019;**60**(3):M184-M203 doi:
30 10.1167/iovs.18-25977[published Online First: Epub Date]].
- 31 102. Huang HM, Chang DS, Wu PC. The Association between Near Work Activities and
32 Myopia in Children-A Systematic Review and Meta-Analysis. *PloS one*
33 2015;**10**(10):e0140419 doi: 10.1371/journal.pone.0140419[published Online First:
34 Epub Date]].
- 35 103. Ip JM, Saw SM, Rose KA, et al. Role of near work in myopia: findings in a sample of
36 Australian school children. *Investigative ophthalmology & visual science*
37 2008;**49**(7):2903-10 doi: 10.1167/iovs.07-0804[published Online First: Epub Date]].
- 38 104. Jones-Jordan LA, Mitchell GL, Cotter SA, et al. Visual activity before and after the
39 onset of juvenile myopia. *Investigative ophthalmology & visual science*
40 2011;**52**(3):1841-50 doi: 10.1167/iovs.09-4997[published Online First: Epub Date]].

- 1 105. Ku PW, Steptoe A, Lai YJ, et al. The Associations between Near Visual Activity and
2 Incident Myopia in Children: A Nationwide 4-Year Follow-up Study. *Ophthalmology*
3 2019;**126**(2):214-20 doi: 10.1016/j.ophtha.2018.05.010[published Online First: Epub
4 Date]].
- 5 106. Lin Z, Gao TY, Vasudevan B, et al. Near work, outdoor activity, and myopia in children
6 in rural China: the Handan offspring myopia study. *BMC Ophthalmol* 2017;**17**(1):203
7 doi: 10.1186/s12886-017-0598-9[published Online First: Epub Date]].
- 8 107. You X, Wang L, Tan H, et al. Near Work Related Behaviors Associated with Myopic
9 Shifts among Primary School Students in the Jiading District of Shanghai: A School-
10 Based One-Year Cohort Study. *PloS one* 2016;**11**(5):e0154671 doi:
11 10.1371/journal.pone.0154671[published Online First: Epub Date]].
- 12 108. Zhang X, Qu X, Zhou X. Association between parental myopia and the risk of myopia
13 in a child. *Exp Ther Med* 2015;**9**(6):2420-28 doi: 10.3892/etm.2015.2415[published
14 Online First: Epub Date]].
- 15 109. Dirani M, Chamberlain M, Garoufalis P, Chen C, Guymer RH, Baird PN. Refractive
16 errors in twin studies. *Twin Res Hum Genet* 2006;**9**(4):566-72 doi:
17 10.1375/183242706778024955[published Online First: Epub Date]].
- 18 110. Hammond CJ, Snieder H, Gilbert CE, Spector TD. Genes and environment in refractive
19 error: the twin eye study. *Investigative ophthalmology & visual science*
20 2001;**42**(6):1232-6
- 21 111. Verhoeven VJ, Hysi PG, Wojciechowski R, et al. Genome-wide meta-analyses of
22 multi-ancestry cohorts identify multiple new susceptibility loci for refractive error and
23 myopia. *Nat Genet* 2013;**45**(3):314-8 doi: 10.1038/ng.2554[published Online First:
24 Epub Date]].
- 25 112. Morgan IG, Rose KA. Myopia: is the nature-nurture debate finally over? *Clin Exp*
26 *Optom* 2019;**102**(1):3-17 doi: 10.1111/cxo.12845[published Online First: Epub
27 Date]].
- 28 113. Saw SM, Hong RZ, Zhang MZ, et al. Near-work activity and myopia in rural and urban
29 schoolchildren in China. *J Pediatr Ophthalmol Strabismus* 2001;**38**(3):149-55
- 30 114. Sensaki S, Sabanayagam C, Verkicharla PK, et al. An Ecologic Study of Trends in the
31 Prevalence of Myopia in Chinese Adults in Singapore Born from the 1920s to 1980s.
32 *Ann Acad Med Singapore* 2017;**46**(6):229-36
- 33 115. Towards universal eye health : a regional action plan for the Western Pacific (2014-
34 2019).
- 35 116. Zaki M, Pardo J, Carracedo G. A review of international medical device regulations:
36 Contact lenses and lens care solutions. *Cont Lens Anterior Eye* 2019;**42**(2):136-46
37 doi: 10.1016/j.clae.2018.11.001[published Online First: Epub Date]].
- 38 117. Saviola JF. The current FDA view on overnight orthokeratology: how we got here and
39 where we are going. *Cornea* 2005;**24**(7):770-1 doi:
40 10.1097/01.icc.0000154234.64359.9a[published Online First: Epub Date]].

- 1 118. Engelhard SB, Shah CT, Sim AJ, Reddy AK. Malpractice Litigation in Cornea and
2 Refractive Surgery: A Review of the WestLaw Database. *Cornea* 2018;**37**(5):537-41
3 doi: 10.1097/ICO.0000000000001534[published Online First: Epub Date]].
- 4 119. Khan-Lim D, Craig JP, McGhee CN. Defining the content of patient questionnaires:
5 reasons for seeking laser in situ keratomileusis for myopia. *J Cataract Refract Surg*
6 2002;**28**(5):788-94 doi: 10.1016/s0886-3350(02)01234-8[published Online First:
7 Epub Date]].
- 8 120. Jeong A, Hau SC, Rubin GS, Allan BD. Quality of life in high myopia before and after
9 implantable Collamer lens implantation. *Ophthalmology* 2010;**117**(12):2295-300 doi:
10 10.1016/j.ophtha.2010.03.055[published Online First: Epub Date]].
- 11 121. Jeong A, Rubin GS, Allan BD. Quality of life in high myopia: implantable Collamer
12 lens implantation versus contact lens wear. *Ophthalmology* 2009;**116**(2):275-80 doi:
13 10.1016/j.ophtha.2008.09.020[published Online First: Epub Date]].
- 14 122. Chen CY, Keeffe JE, Garoufalis P, et al. Vision-related quality of life comparison for
15 emmetropes, myopes after refractive surgery, and myopes wearing spectacles or
16 contact lenses. *J Refract Surg* 2007;**23**(8):752-9
- 17 123. Liu L, Wang F, Xu D, Xie C, Zou J. The application of wide-field laser ophthalmoscopy
18 in fundus examination before myopic refractive surgery. *BMC Ophthalmol*
19 2017;**17**(1):250 doi: 10.1186/s12886-017-0647-4[published Online First: Epub Date]].
- 20 124. Kornberg DL, Klufas MA, Yannuzzi NA, Orlin A, D'Amico DJ, Kiss S. Clinical Utility
21 of Ultra-Widefield Imaging with the Optos Optomap Compared with Indirect
22 Ophthalmoscopy in the Setting of Non-Traumatic Rhegmatogenous Retinal
23 Detachment. *Semin Ophthalmol* 2016;**31**(5):505-12 doi:
24 10.3109/08820538.2014.981551[published Online First: Epub Date]].
- 25 125. Chen SN, Lian Ie B, Wei YJ. Epidemiology and clinical characteristics of
26 rhegmatogenous retinal detachment in Taiwan. *Br J Ophthalmol* 2016;**100**(9):1216-20
27 doi: 10.1136/bjophthalmol-2015-307481[published Online First: Epub Date]].
- 28 126. Edwin H. Ryan CMR, Nora J. Forbes, Yoshihiro Yonekawa, Sushant Wagley, Robert A.
29 Mitra, D. Wilkin Parke, Daniel P. Joseph, Geoffrey G. Emerson, Gaurav K. Shah,
30 Kevin J. Blinder, Antonio Capone, George A. Williams, Dean Elliott, Omesh P.
31 Gupta, Jason Hsu, Carl D. Regillo. Primary Retinal Detachment Outcomes Study
32 (PRO Study): Phakic Retinal Detachment Outcomes—PRO Study Report #2.
33 *Ophthalmology* 2020
- 34 127. Heimann H, Bartz-Schmidt KU, Bornfeld N, et al. Scleral buckling versus primary
35 vitrectomy in rhegmatogenous retinal detachment: a prospective randomized
36 multicenter clinical study. *Ophthalmology* 2007;**114**(12):2142-54 doi:
37 10.1016/j.ophtha.2007.09.013[published Online First: Epub Date]].
- 38 128. Wong CW, Wong WL, Yeo IY, et al. Trends and factors related to outcomes for primary
39 rhegmatogenous retinal detachment surgery in a large asian tertiary eye center. *Retina*
40 2014;**34**(4):684-92 doi: 10.1097/IAE.0b013e3182a48900[published Online First:
41 Epub Date]].

1 129. Meng B, Zhao L, Yin Y, et al. Internal limiting membrane peeling and gas tamponade
2 for myopic foveoschisis: a systematic review and meta-analysis. *BMC Ophthalmol*
3 2017;**17**(1):166 doi: 10.1186/s12886-017-0562-8[published Online First: Epub Date]].

4 130. Peng KL, Kung YH, Hsu CM, Chang SP, Tseng PL, Wu TT. Surgical outcomes of
5 centripetal non-fovea-sparing internal limiting membrane peeling for myopic
6 foveoschisis with and without foveal detachment: a follow-up of at least 3 years. *Br J*
7 *Ophthalmol* 2019 doi: 10.1136/bjophthalmol-2019-314972[published Online First:
8 Epub Date]].

9 131. Lim LS, Ng WY, Wong D, et al. Prognostic factor analysis of vitrectomy for myopic
10 foveoschisis. *Br J Ophthalmol* 2015;**99**(12):1639-43 doi: 10.1136/bjophthalmol-2015-
11 306885[published Online First: Epub Date]].

12 132. Hattori K, Kataoka K, Takeuchi J, Ito Y, Terasaki H. Predictive Factors of Surgical
13 Outcomes in Vitrectomy for Myopic Traction Maculopathy. *Retina* 2018;**38 Suppl**
14 **1**:S23-S30 doi: 10.1097/IAE.0000000000001927[published Online First: Epub Date]].

15 133. Tao J, Wu H, Chen H, et al. Retinoschisis: A Predictive Factor in Vitrectomy for
16 Lamellar Macular Holes in Highly Myopic Eyes. *Ophthalmologica* 2019;**242**(4):208-
17 13 doi: 10.1159/000500927[published Online First: Epub Date]].

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

1 **Figure legends**

2 Figure 1: The future of research in myopia.

3 Figure 2: 12x 12mm Swept source optical coherence tomographic angiography scans of the choroid in
4 a patient with good fixation (A) and a patient with poor fixation (B) Note the presence of motion
5 artefacts (white arrowheads) and artefactual dropout of vascular flow signal due to from segmentation
6 error (white arrow).

7 Figure 3: Ganglion cell- inner plexiform layer (GC-IPL) thickness analysis using spectral domain
8 optical coherence tomography (SD-OCT) in a patient with high myopia and normal tension glaucoma.
9 Red and yellow lines on the OCT B scan image define the anterior and posterior boundaries of the
10 GC-IPL layer respectively. Segmentation error is seen on the OCT B scan in the right eye (white
11 arrow) due to myopic traction maculopathy.

12